In the published article, there was an error in affiliation 1. Instead of “Department of Thoracic Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China”, it should be “Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
sintilimab, thymic carcinoma(TC), therapeutic option, case report, anti-PD-1
Citation
Meng M, Yu B, Luo J, Bai Y, Li L, Chen S, He S and Ma H (2024) Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma. Front. Oncol. 14:1516024. doi: 10.3389/fonc.2024.1516024
Received
23 October 2024
Accepted
25 November 2024
Published
02 December 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2024
Updates
Copyright
© 2024 Meng, Yu, Luo, Bai, Li, Chen, He and Ma.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hu Ma, mahuab@163.com; Sisi He, sisihe1219@163.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.